IVL3021
Stage unconfirmedA once-monthly semaglutide-based obesity injection; a Phase 1 application was filed in Australia in October 2026.
FROM PUBLIC EVENTS · 2026-11-18
Discovery · preclinical Has filed in Australia for the first clinical trial of its once-monthly obesity injection. Also seen: Early clinical · first deals
Roles often seen at this stageResearch & development · Manufacturing & MSAT · Clinical & PV
A developer of long-acting injectables lasting a month or more, built on its IVL-DrugFluidic uniform microsphere manufacturing platform.
A once-monthly semaglutide-based obesity injection; a Phase 1 application was filed in Australia in October 2026.
A long-acting injectable platform that makes uniform particles to control release rate and minimise initial burst.
A long-acting finasteride injection for hair loss that completed a Phase 1 trial in Australia with Daewoong Pharmaceutical.
Filed an application for a Phase 1 trial of IVL3021 in Australia.
Presented non-clinical data on IVL3021 and IVL3024 at the American Diabetes Association meeting (ADA 2026).
Official role guide
Observed 2026-11-18
Information from a role guide does not establish a current vacancy.
A brief based on selected official material, not an exhaustive product or vacancy list.